SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is seeing intense trading volume and sharp price volatility as investors debate the impact of a potential Middle East ceasefire and ongoing institutional skepticism. The community is deeply divided, with bulls pointing to long-term AI and infrastructure projects, while bears highlight significant inventory concerns and recent analyst downgrades.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility as markets react to a tenuous two-week ceasefire between the U.S. and Iran, which has sparked intense debate over the status of the Strait of Hormuz and the viability of the proposed 10-point peace plan. The community is sharply divided, with bears pointing to the sharp correction in energy prices as a market correction while bulls remain skeptical of the deal's longevity and are actively monitoring for potential breakdowns or renewed geopolitical escalations.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing heightened community discussion as investors weigh its potential for massive growth in silicon photonics and AI data center infrastructure against concerns over its premium market valuation and recent financial results. The conversation remains highly polarized, with bulls pointing to record backlogs and critical demand for testing reliability in EV and AI chips, while shorts continue to target the stock due to its volatile price swings and lack of consistent earnings.

Metals Royalty Co Inc. engages in the acquisition and management of critical metals and mineral royalties, streams, and other similar interests. The firm focuses on providing capital to support mineral security and independence in North America in support of accelerating domestic industry growth, including energy, defense and re-industrialization. It operates through Metal and Minerals, and Oil and Gas segments. The company was founded on October 27, 2022, and is headquartered in Calgary, Canada.

Metals Royalty Co Inc. (The)

Metals Royalty Co. (TMCR) is garnering significant attention following its direct listing, with investors closely monitoring its relationship with The Metals Company (TMC) and the potential for deep-sea mining royalties. The community remains divided, with some viewing the low float and royalty structure as a compelling, capital-light opportunity while others express skepticism regarding the company's long-term utility.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as investors react to the company's new role in Elon Musk's 'Terafab' initiative, which aims to scale high-performance AI chip production for robotics and space applications. Community discussion is heavily focused on this strategic foundry partnership as a catalyst for a long-term turnaround, though sentiment remains divided as traders weigh the news against broader market volatility and geopolitical concerns.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny from investors who are frustrated by a lack of communication regarding the timeline for the Helios data center project and what they perceive as underwhelming stock performance relative to its peers. Community sentiment remains highly polarized, with many retail traders accusing management of poor capital allocation and silence, while others continue to hold in anticipation of a potential breakthrough catalyst related to hyperscaler partnerships and long-term infrastructure expansion.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is currently at the center of a high-stakes debate as investors weigh the potential for a binary outcome regarding its lead candidate RP1 ahead of the upcoming PDUFA date. Community sentiment is deeply polarized, with some traders betting on a 'sell the news' event or a second CRL, while others speculate that leadership changes at the FDA could favor an approval surprise.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and retail frustration as investors debate whether the stock is undergoing a "classic fade" or a structural bottoming process ahead of upcoming earnings. While the community is sharply divided by aggressive short-selling activity and ongoing macro-uncertainty, bulls are highlighting recent product launches in business banking and persistent insider buying as catalysts for a potential reversal.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is experiencing high volatility as investors weigh the fragile Iran-Israel ceasefire against reports of ongoing regional conflicts and stalled oil tanker traffic in the Strait of Hormuz. The community is actively debating whether current market strength is a genuine recovery or a "bull trap" manipulated by conflicting geopolitical news cycles and institutional trading activity.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is seeing intense volatility after disappointing 2026 guidance, as management pivots to prioritize user growth over near-term monetization amid concerns that AI-powered language tools are challenging its business model. While some in the community see the sharp sell-off as an attractive entry point for a cash-rich, profitable company, bears and many analysts are aggressively cutting price targets, citing long-term obsolescence risks and frustration with the stock's persistent decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush🏁 $CLYM /said, We are initiating coverage of Climb Bio (CLYM) with an Outperform rating and $12 target. 
$AMGN $OTSKY 
In biotech, being first doesn&#39;t always mean being best and we believe budoprutug and CLYM116 carry differentiated profiles versus standard of care. 
Budoprutug&#39;s indication lineup differs versus other anti-CD19&#39;s like Uplizna; however, we see good rationale for use in disease settings like pMN. 
 
CLYM116 leverages a validated mechanism in IgAN with APRIL and holds potential to improve on both efficacy and dosing interval versus agents like Voyxact. 
 
CLYM also holds a full catalyst calendar: preliminary CLYM116 Phase 1 healthy volunteer data arrives ~mid-2026, with additional budoprutug readouts in 2H26. Cash runway into 2028 enables multiple data cards to turn over. 
 
We model FY33 revenue reaching $1,038M (budoprutug in pMN/ITP; CLYM116 in IgAN) with our base case target at $12/sh. We see downside to ~$3/sh on cash alone, and upside to ~$20/sh on pipeline execution.

Piper Sandler🏁 $CLYM and said, We are initiating coverage on Climb Bio, Inc. (CLYM) with an OW rating and $23 PT where it is developing budoprutug (anti-CD19) across three indications (pMN, ITP, SLE) and CLYM116 (anti-APRIL) in IgAN. 
$CGEM $ZBIO $NVS $SNY TAK ARGX 
Here&#39;s what else Piper Sandler had to say in its note to investors: https://x.com/Quantumup1/status/2022294106731376962?s=20

Piper Sandler🏁 $CLYM and said, We are initiating coverage on Climb Bio, Inc. (CLYM) with an OW rating and $23 PT where it is developing budoprutug (anti-CD19) across three indications (pMN, ITP, SLE) and CLYM116 (anti-APRIL) in IgAN.$CGEM $ZBIO NVS SNY TAK ARGXPiper Sandler... https://t.co/JKx5OcuIHn

quantumup on X (formerly Twitter): "Piper Sandler🏁 $CLYM and said, We are initiating coverage on Climb Bio, Inc. (CLYM) with an OW rating and $23 PT where it is developing budoprutug (anti-CD19) across three indications (pMN, ITP, SLE) and CLYM116 (ant...

StockTwits Web

Climb Bio Inc.

Cullinan Oncology Inc

Zenas Biopharma Inc.

Novartis AG

Sanofi-Aventis

Quantumup

Raymond James🏁 $CLYM Strong Buy/$25 
$AMGN $OTSKY 
Raymond James said in its initiation report—We think the company&#39;s two lead assets: CLYM116 (an anti-APRIL sweeping antibody in development for IgAN), and budoprutug (budo) (an anti-CD19 antibody in development for a variety of rare renal/ autoimmune indications) are poised for significant value creation as important data cards turn over throughout 2026. 
 
Specifically, we anticipate CLYM116 will have initial P1 HV data mid-2026, which should provide meaningful evidence around this drug&#39;s TPP. 
 
Next up, budoprutug will have three POC readouts (in pMN, ITP and SLE) 2H26. 
 
For our part, we only model pMN (primary membranous nephropathy) for this drug, and we anticipate meaningful indications of activity should de-risk this program, creating another inflection opportunity for the stock. Between these two assets, we model U.S. revenue of $205M, $423M, $858M, $1,318M, $1,806M, and $2,173M for FY31-FY36, respectively.

AMGEN Inc.

 /said, We are initiating coverage of Climb Bio (CLYM) with an Outperform rating and $12 target. 


 $OTSKY 
In biotech, being first doesn't always mean being best and we believe budoprutug and CLYM116 carry differentiated profiles versus standard of care. 
Budoprutug's indication lineup differs versus other anti-CD19's like Uplizna; however, we see good rationale for use in disease settings like pMN. 
 
CLYM116 leverages a validated mechanism in IgAN with APRIL and holds potential to improve on both efficacy and dosing interval versus agents like Voyxact. 
 
CLYM also holds a full catalyst calendar: preliminary CLYM116 Phase 1 healthy volunteer data arrives ~mid-2026, with additional budoprutug readouts in 2H26. Cash runway into 2028 enables multiple data cards to turn over. 
 
We model FY33 revenue reaching $1,038M (budoprutug in pMN/ITP; CLYM116 in IgAN) with our base case target at $12/sh. We see downside to ~$3/sh on cash alone, and upside to ~$20/sh on pipeline execution.